Indian Institute of Technology Madras Researchers have developed an Artificial Intelligence-based Mathematical Model to identify cancer-causing alterations in cells.
The algorithm uses a relatively unexplored technique of leveraging DNA composition to pinpoint genetic alterations responsible for cancer progression, a release said.
Cancer is caused due to the uncontrolled growth of cells driven mainly by genetic alterations. In recent years, high-throughput DNA Sequencing has revolutionised the area of cancer research by enabling the measurement of these alterations.
However, due to the complexity and size of these sequencing datasets, pinpointing the exact changes from the genomes of cancer patients is notoriously difficult.
This research was led by Prof. B. Ravindran, Head, RBCDSAI, and Mindtree Faculty Fellow IIT Madras and Dr. Karthik Raman, Faculty Member, Robert Bosch Centre for Data Science and AI (RBCDSAI), IIT Madras, and also the Coordinator, Centre for Integrative Biology and Systems Medicine (IBSE), IIT Madras.
Shayantan Banerjee, a Master’s Student at IIT Madras, performed the experiments and analysed the data.
The results have been recently published in the peer-reviewed International Journal Cancers.
Prof. B. Ravindran, Head, Robert Bosch Centre for Data Science and AI (RBCDSAI), IIT Madras, said, “One of the major challenges faced by cancer researchers involves the differentiation between the relatively small number of ‘driver’ mutations that enable the cancer cells to grow and the large number of ‘passenger’ mutations that do not have any effect on the progression of the disease.”
The Practical Applications of this Research include:
- Given their vital role in tumour progression and development, computational prioritisation of cancer driver mutations is an active area of research. Understanding the underlying mechanism of these alterations will help identify the most appropriate treatment strategy for a patient in an approach known as ‘precision oncology’
- Tailoring treatments, not only to a specific illness but also to a specific person’s genetic make-up is challenging and requires extensive cataloging of the “driver” variants of interest.
The researchers hope that the driver mutations predicted through their mathematical model will ultimately help discover potentially novel drug targets and will advance the notion of prescribing the “right drug to the right person at the right time.”
Dr. Karthik Raman, Associate Professor, Department of Biotechnology, Bhupat and Jyoti Mehta School of Biosciences, IIT Madras, said, “In most of the previously published techniques researchers typically analysed DNA sequences from large groups of cancer patients, comparing sequences from cancer as well as normal cells and determined whether a particular mutation occurred more often in cancer cells than random. However, this ‘frequentist’ approach often missed out on relatively rare driver mutations.”
Karthik Raman said, “Detecting driver mutations, particularly rare ones, is an exceptionally difficult task, and the development of such methods can ultimately accelerate early diagnoses and the development of personalised therapies.”
In this study, the researchers decided to look at this problem from a different perspective. The main goal was to discover patterns in the DNA sequences – made up of four letters, or bases, A, T, G and C surrounding a particular site of alteration.
The underlying hypothesis was that these patterns would be unique to individual types of mutations – drivers and passengers, and therefore could be modelled mathematically to distinguish between the two classes. Using sophisticated AI techniques, the researchers developed a novel prediction algorithm, NBDriver and tested its performance on several open-source cancer mutation datasets.
Ravindran added, “Our model could distinguish between well-studied drivers and passenger mutations from cancer genes with an accuracy of 89%. Furthermore, combining the predictions from NBDriver and three others commonly used driver prediction algorithms resulted in an accuracy of 95%, significantly outperforming existing models.”
Karthik Raman added, “Interestingly, NBDriver could accurately identify 85% of the rare driver mutations from patients diagnosed with Glioblastoma Multiforme (GBM), a particularly aggressive type of cancer affecting the brain or spine.”
NBDriver is available publicly and can be used to obtain predictions on any user-defined set of mutations. In short, given a new mutation and its surrounding DNA makeup, one would be able to predict its class – driver or passenger.
The Next Steps of the RBCDSAI Research Team in this topic include:
- Developing an easy-to-use web interface that will enable cancer researchers to get predictions on their preferred set of variants.
- Further studies on the context of these mutations, and how they impact the evolution of cancer.
- NBDriver will also be part of a broader cancer genomic sequence analysis “pipeline” being developed at RBCDSAI & IBSE.
